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Abstract
Background: Chronic kidney disease (CKD) is associated with cardiovascular events. Adipocyte fatty acid-binding
protein (A-FABP) plays an important role in atherosclerosis. We investigated whether plasma A-FABP is involved in
renal function in patients with stable angina pectoris.
Methods: A total of 221 patients with significant coronary artery stenosis were enrolled after coronary
angiography. CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m
2. The severity
of coronary stenosis was assessed using a modified Gensini score and coronary angiography. Serum A-FABP levels
were determined by enzyme-linked immunosorbent assay.
Results: Serum A-FABP levels were significantly correlated with both eGFR (r = -0.41, p < 0.01) and the severity of
coronary artery stenosis (r = 0.16, p = 0.02), and these relationships remained significant after adjusting for
confounding factors. The prevalence of CKD and multi-vessel disease was significantly higher among patients with
serum A-FABP levels above the median value of 20.3 ng/ml than among patients with serum A-FABP levels below
the median value (57% vs. 27%, p < 0.01 and 64% vs. 48%, p = 0.02, respectively). Multivariate analysis revealed
that the presence of three-vessel disease in comparison with single-vessel disease was independently associated
with the higher A-FABP (per doubling) (odds ratio; 2.26, 95% confidential interval; 1.28-3.98, p < 0.01) and tended
to be associated with the lower eGFR (p = 0.06).
Conclusion: Serum A-FABP may have a significant role in the interplay between renal dysfunction and coronary
atherosclerosis.
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Background
Obesity and obesity-associated disorders, including insu-
lin resistance, type 2 diabetes, dyslipidemia, and hyper-
tension, are rapidly increasing in developed countries. In
association with weight gain, the hyperplasia and hyper-
trophy of adipocytes influence the secretion pattern of
adipocyte-derived proteins, adipokines, by adipose tissue.
Recent evidence shows that adipokines contribute to the
increased metabolic and cardiovascular risk among
obese patients [1]. Among those adipokines, adipocyte
fatty acid-binding protein (A-FABP), also known as aP2
or FABP4, is small intracellular lipid-binding protein
which is expressed abundantly in adipocytes and acti-
vated macrophages [2]. Now, there are nine types of
FABPs, showing tissue-specific expression patterns, and
s e v e r a lm e m b e r so ft h eF A B Pf a m i l yh a v eb e e ns h o w n
to have important roles in regulating metabolism and
have links to the development of insulin resistance and
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play an essential regulatory role in energy metabolism
and inflammation [4], and found not only in tissue, but
also in blood stream [5].
The pathophysiological role of A-FABP has been
investigated in murine experimental models and clinical
studies. In mice, A-FABP deficiency ameliorates the
development of insulin resistance in diet-induced obesity
[2], type 2 diabetes [6], and atherosclerosis in models of
hypercholesterolemia [7]. Clinically, A-FABP is detected
in human serum [5]. Higher serum A-FABP levels are
used to predict and diagnose obesity-related metabolic
syndrome and type 2 diabetes [8,9]. Previous studies
also showed that serum A-FABP levels are associated
with carotid intima-media thickness [10], coronary
artery disease [11], the number of stenotic coronary
arteries [12], and coronary plaque volume, as deter-
mined by intravascular ultrasound [13]. Furthermore,
the involvement of A-FABP in atherosclerosis is sup-
ported by a genetic study in humans. Carriers of the
T87C polymorphism have lower serum triglyceride
levels, demonstrating a reduced cardiovascular risk [14].
These findings demonstrate that A-FABP may play a
critical role in the development of metabolic syndrome,
type 2 diabetes, and cardiovascular disease.
Although the association between A-FABP and several
metabolic parameters has been studied in detail, little is
known about the relationship between this adipokine
and renal function. One study showed that serum A-
FABP concentrations in patients with chronic hemodia-
lysis are higher than those in control patients without
hemodialysis [15], although serum A-FABP levels in
patients with a mild to moderate decrease in glomerular
filtration rate (GFR) remain untested. Furthermore, the
association between serum A-FABP, eGFR, and severity
of coronary artery disease has not been evaluated.
Therefore, we determined serum A-FABP levels in 221
patients with stable angina pectoris and assessed the
correlation between serum A-FABP levels and biochem-
ical measures of renal function, as well as the severity of
coronary artery disease.
Methods
Study group
This study included 221 patients with stable angina pec-
toris who underwent coronary angiography between
April 2008 and September 2009 at Kagawa Prefectural
Central Hospital, Japan. Patients who had 75% or
greater organic stenosis of at least one major coronary
artery or who had previously undergone percutaneous
transluminal coronary angioplasty were included.
Patients with chronic hemodialysis, acute coronary syn-
drome, recent (within 4 weeks) myocardial infarction, or
malignancies were excluded. The study protocol com-
plied with the Declaration of Helsinki and was approved
by the Ethics Committees of the institute. Written
informed consent was obtained from all patients before
study enrollment.
Clinical and biochemical assessments
Blood samples were taken after overnight fasting. The
serum was separated and stored at -80°C, and serum
levels of A-FABP (Biovendor Laboratory Medicine,
Modrice, Czech Republic) and high-sensitivity C-reactive
protein (hs-CRP; R&D Systems, Minneapolis, MN, USA)
were measured by enzyme-linked immunosorbent assay
[13]. The performance characteristics of these assays
were < 7% and < 8% intra-assay coefficient of variation
(CV), and < 5% and < 7% inter-assay CV for A-FABP
and hs-CRP, respectively.
Risk factors were defined as follows. Diabetes was con-
firmed using the criteria of the American Diabetes Asso-
ciation [16] or by a history of treatment for diabetes
mellitus. Dyslipidemia was defined as one or more of
the following criteria: (1) serum triglyceride ≥ 150 mg/
dl; (2) high-density lipoprotein (HDL)-cholesterol < 40
mg/dl; (3) low-density lipoprotein (LDL)-cholesterol ≥
140 mg/dl; and (4) current use of lipid-lowering medica-
tion. Hypertension was defined as a sitting blood pres-
sure ≥ 140/90 mmHg or current use of antihypertensive
medication. Smoking status was determined and classi-
fied as current smoker or not. The estimated GFR
(eGFR) was calculated using the equation put forth by
the Modification of Diet in Renal Disease (MDRD)
Study Group [17], with coefficients modified for Japa-
nese patients [18]: eGFR (ml/min/1.73 m
2) = 194 ×
(serum creatinine)
-1.094 ×( a g e )
-0.287 (x0.739 if female).
The distribution of the eGFR was divided into three
categories: less than 60 (moderately decreased eGFR, n
= 93), 60-89 (mildly decreased eGFR, n = 106) and at
least 90 ml/min/1.73 m
2 (normal eGFR, n = 22).
Patients with end stage renal disease were not included.
Chronic kidney disease (CKD) was defined as eGFR <
60 ml/min/1.73 m
2.
Coronary angiography
Coronary angiography was performed according to stan-
dard methods. After intracoronary injection of isosor-
bide dinitrate, angiograms were obtained in two or more
views. The coronary angiogram was scored by two inde-
pendent investigators. The stenosis score is a modified
Gensini score [19]. Briefly, the most severe stenosis in
each of eight segments was graded according to severity,
from 1 to 4. The scores in each of the eight segments
were added to provide a total stenosis score out of a
maximum of 32.
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Continuous variables are presented as mean ± standard
deviation (SD) or median (interquartile range [(IQR])
values, and differences between groups were analyzed
using an unpaired Student’s t test. Data that were not
normally distributed, as determined using the Kolmo-
gorov-Smirnov test, were logarithmically transformed
before linear regression analysis. Categorical variables
are presented as frequency counts and corresponding
percentages, and intergroup comparisons were analyzed
using the chi-square test. Associations between serum
A-FABP and other parameters were first analyzed by
simple linear regression analysis and then by multivari-
ate logistic regression analysis. To assess the association
between serum A-FABP level and the presence of CKD
or three-vessel coronary artery disease, logistic regres-
sion analyses were performed. In those analyses, factors
that were associated with the dependent variable at p <
0.05 in the univariate analysis were entered into the
multivariate model. In multivariate model, diabetes was
selected as a covariate because fasting glucose levels,
hemoglobinA1c, the homeostasis model assessment
ratio are confounding factors of diabetes. Statistical sig-
nificance was defined as p < 0.05. Statistical analyses
were performed using SPSS 16.0 for Windows (SPSS
Inc., Chicago, IL, USA).
Results
Patient characteristics
The clinical characteristics of the study population are
shown in Table 1. Patients with eGFR levels < 60, 60-
89, or > 90 ml/min/1.73 m
2 differed in age, the presence
of hypertension, smoking status, serum triglycerides
levels, uric acid levels, fasting glucose levels, hemoglobi-
nA1c, the homeostasis model assessment ratio (HOMA-
R), and serum A-FABP levels but not in the number of
diseased vessels or the stenosis score. The eGFR value
was significantly lower among patients with hyperten-
sion than among patients without hypertension (mean ±
SD, 66.3 ± 18.1 ml/min/1.73 m
2 vs. 73.1 ± 18.6 ml/min/
1.73 m
2, p < 0.01 by Student’s t test). The eGFR value
was significantly higher among smokers than among
non-smokers (76.1 ± 17.3 ml/min/1.73 m
2 vs. 63.9 ±
18.5 ml/min/1.73 m
2, p < 0.01). The eGFR value did not
vary by the presence or absence of diabetes mellitus or
dyslipidemia, gender, or the use of specific medications
(data not shown). The stenosis score was significantly
higher among patients with diabetes mellitus than
among patients without diabetes mellitus (1.9 ± 0.8 vs.
1.6 ± 0.7, p < 0.01). The stenosis score did not vary by
the presence or absence of hypertension or dyslipidemia,
smoking status, gender, or the use of specific medica-
tions (data not shown). The prevalence of CKD and
multi-vessel disease based on the median value of serum
A-FABP (20.7 ng/ml) were shown in Figures 1A and 1B.
T h ep r e v a l e n c eo fC K Da n dm u l t i - c o r o n a r yv e s s e ld i s -
ease was significantly higher among patients with serum
A-FABP levels over the median value than among
patients with serum A-FABP levels less than the median
value (57% vs. 27%, p < 0.01 and 64% vs. 48%, p = 0.02,
respectively).
Serum A-FABP levels and other biochemical parameters
Serum A-FABP levels were significantly higher among
females than among males (median (IQR), 30.9 (26.7)
Table 1 Patient characteristics in this study
eGFR (ml/min/1.73 m
2)
ALL < 60 60-89 ≥ 90
(n =
221)
(n =
93)
(n =
106)
(n =
22)
p
Age (years) 71 ± 10 76 ± 8 68 ± 10 62 ± 11 <
0.01
Male, n (%) 185(84) 74(80) 92(87) 19(86) 0.36
Body mass index (kg/m
2) 24.7 ±
3.6
24.5 ±
3.7
25.0 ±
3.4
24.0 ±
4.5
0.29
Hypertension, n (%) 157(71) 77(83) 77(73) 12(55) 0.02
Dyslipidemia, n (%) 183(83) 75(81) 89(84) 19(86) 0.72
Diabetes Mellitus, n (%) 96(43) 31(33) 53(50) 12(54) 0.03
Smoking (Yes) 28(13) 5(5) 18(16) 5(23) 0.02
LDL-Cholesterol (mg/dl) 102 ±
28
100 ±
28
103 ±
29
10.4 ±
26
0.77
HDL-Cholesterol (mg/dl) 43 ± 12 42 ± 11 44 ± 12 44 ± 11 0.59
Triglycerides (mg/dl) 163(79) 155
(107)
169(61) 167(68) <
0.01
Uric acid (mg/dl) 5.8 ±
1.6
6.4 ±
1.6
5.5 ±
1.4
4.9 ±
1.6
<
0.01
Fasting blood glucose
(mg/dl)
100(25) 96(18) 102(34) 104(28) <
0.01
HOMA-R 1.7(1.5) 1.7(1.3) 1.8(1.7) 1.3(1.1) <
0.01
HemoglobinA1c (%) 5.6(1.2) 5.4(0.8) 5.7(1.2) 5.9(1.0) 0.04
hs-CRP(mg/l) 0.97
(2.35)
1.25
(3.27)
0.82
(1.79)
1.59
(2.72)
0.10
Serum A-FABP (ng/ml) 20.3
(13.6)
26.9
(19.5)
19.6
(11.1)
16.1(4.7) <
0.01
Number of diseased
vessels
1.8 ±
0.8
1.9 ±
0.8
1.7 ±
0.8
1.5 ±
0.7
0.12
Stenosis score 9.9 ±
4.9
9.3 ±
4.5
9.5 ±
5.8
10.2 ±
5.1
0.71
Medications 28(13) 5(5) 18(16) 5(23) 0.02
ACEI/ARB, n (%) 119(54) 39(43) 66(62) 14(64) 0.18
CCBs, n (%) 120(54) 48(52) 57(38) 15(68) 0.39
b-blockers, n (%) 73(33) 27(29) 40(38) 6(27) 0.36
Statins, n (%) 126(57) 49(52) 63(59) 14(63) 0.50
Data are presented as the mean ± SD, median (IQR), or frequency counts
(percentages), as appropriate. LDL-C, low-density lipoprotein cholesterol; HDL-
C, high-density lipoprotein cholesterol; FBS, fasting blood glucose; HOMA-R,
homeostasis model assessment ratio; hs-CRP, high-sensitivity C-reactive
protein; eGFR, estimated glomerular filtration rate; A-FABP, adipocyte fatty
acid-binding protein: ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin II receptor blocker; CCBs, calcium channel blockers
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Page 3 of 8ng/ml vs. 19.79(11.5) ng/ml, p < 0.01). Serum A-FABP
levels were also significantly higher in patients with
hypertension than those without hypertension (21.4
(14.9) ng/ml vs. 18.5(13.3) ng/ml, p = 0.02). Serum A-
FABP levels did not vary by the presence or absence of
diabetes mellitus, dyslipidemia, smoking status, or the
use of specific medications (data not shown). As shown
in Table 2 and Figure 2, serum A-FABP levels correlated
significantly with gender, eGFR levels (Figure 2A), body
mass index, hs-CRP levels, and stenosis scores (Figure
2B). Multiple linear regression analysis revealed that the
serum A-FABP level was independently associated with
the eGFR value and the stenosis score along with gender
or body mass index. Next, the associations between
CKD and other biochemical parameters were assessed
(Table 3). Multiple logistic regression analysis revealed
that the serum-A-FABP level (per doubling) was inde-
pendently associated with CKD, with an odds ratio of
3.7 (95% confidential interval; 2.14-6.461, p < 0.01).
Finally, the associations of the severity coronary artery
disease with the levels of eGFR and serum A-FABP
were analyzed by logistic regression analysis (Table 4).
Multivariate analysis revealed that the presence of three-
vessel disease in comparison with single-vessel disease
was independently associated with the higher A-FABP
level(per doubling) (odds ratio; 2.26, 95% confidential
interval; 1.28-3.98, p < 0.01) and tended to be involved
in the lower eGFR value (per ml/min/1.73 m
2)(odds
ratio; 0.98, 95% confidential interval; 0.96-1.00, p <
0.06).
Discussion
We demonstrated that the serum A-FABP level was
independently correlatedw i t ht h ee G F Rv a l u ei n
patients with stable angina pectoris without hemodialy-
sis. Serum A-FABP may be a novel marker of renal
function as well as the severity of coronary artery
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Figure 1 Prevalence of CKD (A) and multi-vessel disease (B)
among patients grouped according to the median value of
serum A-FABP (20.3 ng/ml).
Table 2 Relationship between serum A-FABP and other
parameters
Univariate Multivariate
rpb p
Age 0.09 0.14
Gender (male = 1) -0.33 < 0.01 -0.31 < 0.01
Body mass index 0.35 < 0.01 0.35 < 0.01
Uric acid 0.12 0.08
LDL-cholesterol 0.06 0.37
HDL-cholesterol -0.12 0.09
Triglycerides* -0.05 0.50
HbA1c* 0.06 0.46
HOMA-R* 0.11 0.10
hs-CRP* 0.15 0.03 0.05 0.32
eGFR -0.41 < 0.01 -0.40 < 0.01
Stenosis score 0.16 0.02 0.15 < 0.01
Values indicated with * were included in the model after log-transformation.
In the model, R
2 = 0.42
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eGFR. Our findings suggest that circulating A-FABP
may have an important role in the interplay between
renal dysfunction and the development of coronary
atherosclerosis.
The mechanism underlying the relationship between
A-FABP and eGFR has not been fully clarified. Sommer
et al. reported that serum A-FABP levels are more than
10-fold higher among patients with chronic hemodialysis
than among controls [15]. In addition to A-FABP, circu-
lating levels of adiponectin, leptin, and retinol-binding
protein 4 have been reported to be higher among
patients with chronic hemodialysis than among controls
[20-22]. These results suggest that renal elimination
plays an important role in determining the serum
concentration of various adipocyte-derived proteins,
including adiponectin, leptin, retinol-binding protein 4,
and A-FABP, although the causal relationship between
the elevated circulating A-FABP and renal dysfunction
remains unclear. More mechanistic studies involving
animal experiments are necessary to prove the concept
that A-FABP is not only secreted from adipose tissue
but also is cleared by the kidneys. Furthermore, markers
of renal function should be included in future studies as
potential confounders when examining the physiology
and regulation of A-FABP in humans.
The finding that serum A-FABP was independently
associated with the severity of coronary atherosclerosis
is in agreement with our previous findings [11]. In
human, recent study showed that circulating A-FABP
levels were shown to be associated with vascular inflam-
mation, as measured using (18)F-fluorodeoxyglucose
positron emission tomography [23]. Peeters et al.
reported that serum A-FABP levels and A-FABP con-
centrations in human carotid tissue were associated with
the vulnerability of carotid plaques [24]. On the other
hand, experimental studies showed that A-FABP plays a
critical role in the development of atherosclerosis by
coordinating the cholesterol-trafficking and inflamma-
tory activity of macrophages [25]. A-FABP deficiency
reduces foam cell formation in response to oxidized
LDL and increases the cholesterol efflux pathway [25].
A-FABP-deficient mice also show a significant decrease
in vascular atherosclerosis in the absence of differences
in serum lipid levels or insulin sensitivity in a model of
hyperlipidemia, and this effect is due OR has been
attributed to the effects of A-FABP on macrophages [7].
In addition, A-FABP can activate several key inflamma-
tory pathways. In A-FABP-deficient macrophages, the
activity of the peroxisome proliferator-activated receptor
g and the liver X receptor a is enhanced, leading to sup-
pressed transcription of several inflammatory genes
[26,27]. In addition, the NF-B pathway is impaired,
resulting in suppression of inflammatory function [25].
The physiological significance of increased serum A-
FABP in renal failure remains to be elucidated. CKD is
strongly associated with the development of athero-
sclerotic lesions and mortality from cardiovascular dis-
ease [28]. Because A-FABP has been reported to induce
dyslipidemia and atherosclerosis in animal models [7],
A - F A B Pm a yc o n t r i b u t et ot h es i g n i f i c a n t l yi n c r e a s e d
cardiovascular mortality among patients with CKD.
Recently, Furuhashi et al. reported that the circulating
A-FABP level is a predictor of cardiovascular events in
end-stage renal disease [29]. Peeters et al. also reported
that the serum A-FABP levels in human carotid ather-
manous plaques were associated with adverse cardiovas-
cular events [30]. Regarding a circulating FABP, recent
studies showed heart -FABP may represent a marker for
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predictor of cardiovascular events are promising. Taken
together with our findings, the elevated serum A-FABP
in patients with CKD may be involved in plaque vulner-
ability in atherosclerotic lesions and may predict a
future cardiovascular event.
The role of circulating A-FABP as an atherogenic fac-
tor remains unknown. A recent study reported that A-
FABP directly and acutely depresses the contraction of
cardiomyocytes by decreasing intracellular Ca
2+ levels
[32], suggesting that a direct bioactive role for A-FABP
may exist in cells. It is well established that A-FABP is
expressed by adipocytes, which may be major contribu-
tors to circulating A-FABP levels. Therefore, A-FABP
secreted from adipose tissue may contribute to the
development of atherosclerosis. Future studies should
address whether circulating A-FABP induces athero-
sclerosis by activating macrophages and vascular cells.
Limitations
This study has several limitations that should be consid-
ered when interpreting the results. First, the sample size
was not large. Second, our study was cross-sectional,
which does not allow us to determine if a causal rela-
tionship exists between A-FABP and renal dysfunction
or between A-FABP and the development of coronary
artery disease. Prospective population-based studies are
needed to address whether serum A-FABP is a risk fac-
tor for CKD or coronary artery disease. Finally, we
enrolled patients who were admitted to the hospital for
coronary angiography in order to obtain more accurate
data on coronary stenosis. Most of our patients had
established risk factors for coronary artery disease, and
so, the generalizability of our findings to other patient
populations is unclear.
Conclusions
We demonstrated that the serum A-FABP level was
independently associated with CKD. Serum A-FABP
may be a marker of renal dysfunction and may be asso-
ciated with the severity of coronary artery disease in
patients with a mild to moderate decrease in eGFR.
Table 3 Relationship between CKD and other parameters
Crude Adjusted
Factors OR (95%CI) p OR (95%CI) p
Age (per year) 1.11(1.08-1.16) < 0.01 1.11(1.07-1.17) < 0.01
Male 0.59(0.29-1.22) 0.16
Smoking (yes) 0.28(0.10-0.76) 0.01 0.44(0.13-1.49) 0.18
Hypertension (yes) 2.19(1.13-4.29) 0.03 1.25(0.54-2.914) 0.56
Diabetes (yes) 0.53(0.31-0.93) 0.03 0.62(0.29-1.33) 0.22
Fasting blood glucose (per doubling) 0.16 (0.05-0.46) < 0.01
HOMA-R* (per doubling) 0.99(0.78-1.27) 0.97
HbA1c (per doubling) 0.192(0.05-0.74) 0.02
Dyslipidemia 0.77(0.38-1.56) 0.47
HDL (per mg/dl) 0.99(0.97-1.01) 0.31
LDL (per mg/dl) 0.99(0.98-1.00) 0.49
Triglycerides (per doubling) 0.44(0.27-0..71) < 0.01 0.49(0.26-0.93) 0.03
Uric acid (per mg/dl) 1.59(1.29-1.94) < 0.01 1.70 (1.02-2.22) < 0.01
A-FABP (per doubling) 3.03(1.94-4.72) < 0.01 3.14(1.89-5.31) 0.01
In the model, R
2 = 0.34
Table 4 Relationship between severe coronary artery
disease and other parameters
Crude Adjusted
Factors OR (95%CI) p OR (95%CI) p
Age (per year) 1.01(0.98-1.04) 0.55
Male 1.39(0.51-3.79) 0.51
Smoking (yes) 1.16(0.39-3.40) 0.79
Hypertension (yes) 1.63(0.69-3.84) 0.26
Diabetes (yes) 2.63(1.29-5.36) <
0.01
3.20(1.43-
7.17)
<
0.01
FBS (per doubling) 3.6(1.26-10.53) 0.02
HOMA-R (per doubling) 1.31(0.95-1.80) 0.10
HbA1c (per doubling) 5.95(1.21-
29.14)
0.03
Dyslipidemia 1.72(0.64-4.66) 0.28
Triglycerides (per
doubling)
1.11(0.63-1.95) 0.72
HDL (per mg/dl) 0.97(0.94-1.00) 0.05
LDL (per mg/dl) 0.99(0.98-1.00) 0.16
Uric acid (per mg/dl) 1.02(0.82-1.27) 0.87
eGFR (per ml/min/
1.73m2)
0.97(0.95-0.99) <
0.01
0.98(0.95-
1.00)
0.06
A-FABP (per doubling) 2.97(1.77-4.98) <
0.01
2.26(1.28-
3.98)
0.01
In the model, R
2 = 0.16
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in the interplay between renal dysfunction and the
development of coronary atherosclerosis. Further studies
with larger cohorts derived from the general population
are necessary to evaluate whether circulating A-FABP
levels can be used to predict the risk of renal dysfunc-
tion and the development of coronary artery disease.
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